-
From nothing to abundance for hemophilia with inhibitors. Blood. 2026 Feb 26; 147(9):905-906. Young G. PMID: 41746639.
-
The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. J Thromb Haemost. 2026 Feb 03. van Stam LE, Daisy Horstman BJ, Angchaisuksiri P, Carcao M, Kenet G, Königs C, Mahlangu J, Mancuso ME, Rezende SM, Sidonio RF, Srivastava A, Young G, Fijnvandraat K, Gouw SC. PMID: 41643940.
-
Emicizumab in infants: not just cost-effective but mandatory. Blood Adv. 2025 Dec 23; 9(24):6354-6355. Young G. PMID: 41379501; PMCID: PMC12848343.
-
Deconstructing gene therapy in hemophilia for the clinician. Hematology Am Soc Hematol Educ Program. 2025 Dec 05; 2025(1):659-667. Young G. PMID: 41348030; PMCID: PMC12891452.
-
Multisite Validation of a Venous Thrombosis Risk Model in Critically Ill Children Through the CHAT Consortium. Blood. 2025 Nov 24. Jaffray J, Branchford BR, Alleyne MM, Amankwah E, Faustino EVS, Zakai NA, Sochet AA, Stillings A, Krava E, Young G, Goldenberg NA. PMID: 41284641.
-
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025 Jun 19; 145(25):2966-2977. Young G, Kavakli K, Klamroth R, Matsushita T, Peyvandi F, Pipe SW, Rangarajan S, Shen MC, Srivastava A, Sun J, Tran H, You CW, Zülfikar B, Menapace LA, Zhang C, Shen Y, Puurunen M, Demissie M, Kenet G. PMID: 40053895; PMCID: PMC12824673.
-
Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. Haemophilia. 2025 Jul; 31(4):799-806. Astermark J, Miesbach W, Coppens M, Gielen S, Twisk J, Dolmetsch R, Verweij S, Monahan PE, Ewenstein BM, Nuthalapati S, Galante N, Young G, HOPE-B study investigators. PMID: 40534246; PMCID: PMC12311899.
-
Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice. Res Pract Thromb Haemost. 2025 May; 9(4):102926. Sidonio RF, Young G, Escuriola Ettingshausen C, Mahlangu J, Ozelo MC, Srivastava A, Windyga J, Lee HY, Lelli A, Pipe SW. PMID: 40808796; PMCID: PMC12346059.
-
Reply to Letter to the Editor: "Deconstructing the ISTH Hemophilia Guidelines for the Clinician": comment from Mancuso-ME et al. J Thromb Haemost. 2025 May; 23(5):1737-1738. Young G, Lassila R, Mason J, Prasca S. PMID: 40306822.
-
Invitation and welcome to the 2025 ISTH Congress. J Thromb Haemost. 2025 May; 23(5):1461-1463. Young G, Lassila R, Wolberg AS. PMID: 40306814.
-
Global Comparative Antithrombin Field Study: Impact of Laboratory Assay Variability on the Assessment of Antithrombin Activity Measurement at Fitusiran Clinical Decision-Making Points. Haemophilia. 2025 May; 31(3):566-574. Chhabra ES, Sadeghi-Khomami A, Liu M, Young G, Pipe SW, Ozelo MC, Camus CL, Toh ML, Demissie M, Peyvandi F. PMID: 40254822; PMCID: PMC12175104.
-
Extended-phase anticoagulant treatment of acute venous thromboembolism in children: a cohort study from the EINSTEIN-Jr phase 3 trial. Lancet Haematol. 2025 May; 12(5):e357-e364. Male C, Lensing AWA, Chan AKC, Kenet G, Young G, Bhat R, Pap AF, Kubitza D, Prins MH, Monagle P, EINSTEIN-Jr Phase 3 Investigators. PMID: 40222370.
-
Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials. Blood Vessel Thromb Hemost. 2025 Aug; 2(3):100069. Young G, Mahlangu J, Boggio LN, Carcao M, Dargaud Y, Escobar M, Giermasz A, Hermans C, Kuriakose P, Miesbach W, Nance D, Rafique A, Sidonio RF, Vilchevska KV, Wang M, Pipe SW. PMID: 40765904; PMCID: PMC12320391.
-
Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance. J Thromb Haemost. 2025 Jul; 23(7):2086-2094. Konkle BA, Peyvandi F, Foster GR, Hermans C, La Mura V, Leavitt AD, Lillicrap D, Mahlangu J, Ozelo MC, Pipe S, Recht M, Srivastava A, Young G, Miesbach W. PMID: 40090623.
-
Fondaparinux Approval in Pediatrics: The Story of My Third Child. Pediatr Blood Cancer. 2025 May; 72(5):e31638. Young G. PMID: 40029103.
-
Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study. Res Pract Thromb Haemost. 2025 Feb; 9(2):102705. Angchaisuksiri P, von Mackensen S, Apte S, Benson G, Eichler H, Findley A, Matsushita T, Mazini Tavares CM, Puggaard Ravn M, Sathar J, Villarreal Martinez L, Young G. PMID: 40166710; PMCID: PMC11957488.
-
Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors. Blood Adv. 2025 Jan 28; 9(2):265-269. Young G. PMID: 39418639; PMCID: PMC11782813.
-
Accurate evaluation of factor VIII activity of efanesoctocog alfa in the presence of emicizumab. J Thromb Haemost. 2025 May; 23(5):1516-1521. Nougier C, Pipe SW, Pabinger I, Pouplard C, Schutgens REG, Hermans C, Young G, Sexton E, Quehenberger P, Guery EA, Huisman A, Van Dievoet MA, Marquez E, Dargaud Y. PMID: 39798924.
-
Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors. Haemophilia. 2025 Jan; 31(1):78-86. Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, Hermans C, Jiménez-Yuste V, Lewandowska M, Mahlangu J, Meeks S, Miesbach W, Recht M, Salinas V, Chrisentery-Singleton T, Bonzo D, Mitchell IS, Wilkinson TA, Young G. PMID: 39676340; PMCID: PMC11780187.
-
Deconstructing the ISTH hemophilia guidelines for the clinician. J Thromb Haemost. 2025 May; 23(5):1483-1495. Young G, Lassila R, Mason J, Prasca S. PMID: 39617189.
-
Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024 Dec; 11(12):e891-e904. Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, Jiménez Yuste V, Matsushita T, Høgh Nielsen AR, Sathar J, Sutton C, Šaulyte Trakymiene S, Tran H, Villarreal Martinez L, Wheeler AP, Windyga J, Young G, Thaung Zaw JJ, Eichler H. PMID: 39521008.
-
CHIEF: A retrospective self-control study of children with severe hemophilia A without inhibitors comparing emicizumab to FVIII prophylaxis. Pediatr Blood Cancer. 2024 Dec; 71(12):e31351. Mashiach D, Mead P, Carneiro K, Malvar J, Knight S, Young G. PMID: 39367598.
-
Real-world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi-institutional case series. Haemophilia. 2024 Nov; 30(6):1321-1331. Youkhana K, Batsuli G, Acharya S, Khan O, Tran DQ, Dvorak A, Recht M, Young G, Sidonio R, Abajas Y. PMID: 39297369; PMCID: PMC11659498.
-
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial. Blood. 2024 05 30; 143(22):2256-2269. Kenet G, Nolan B, Zulfikar B, Antmen B, Kampmann P, Matsushita T, You CW, Vilchevska K, Bagot CN, Sharif A, Peyvandi F, Young G, Negrier C, Chi J, Kittner B, Sussebach C, Shammas F, Mei B, Andersson S, Kavakli K. PMID: 38452197; PMCID: PMC11181353.
-
Simoctocog alfa (Nuwiq®) in children: early steps in life's journey for people with severe hemophilia A. Ther Adv Hematol. 2024; 15:20406207241245511. Klukowska A, Sidonio RF, Young G, Mancuso ME, Álvarez-Román MT, Bhatnagar N, Jansen M, Knaub S. PMID: 38737006; PMCID: PMC11085023.
-
Emicizumab is well tolerated and effective in people with congenital hemophilia A regardless of age, severity of disease, or inhibitor status: a scoping review. Res Pract Thromb Haemost. 2024 May; 8(4):102415. Young G, Pipe SW, Kenet G, Oldenburg J, Safavi M, Czirok T, Nissen F, Mahlangu J. PMID: 38812987; PMCID: PMC11135026.
-
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024 04 04; 143(14):1355-1364. Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. PMID: 38127586; PMCID: PMC11033591.
-
How I treat pediatric venous thromboembolism in the DOAC era. Blood. 2024 02 01; 143(5):389-403. Bhat RV, Young G, Sharathkumar AA. PMID: 37390311; PMCID: PMC10862368.
-
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Res Pract Thromb Haemost. 2024 Jan; 8(1):102306. Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, Mahlangu J, Lehle M, Niggli M, Castaman G, Jiménez-Yuste V, Shima M, Négrier C, Schmitt C. PMID: 38282901; PMCID: PMC10818085.
-
Delivery of gene therapy in haemophilia treatment centres in the United States: Practical aspects of preparedness and implementation. Haemophilia. 2023 Nov; 29(6):1430-1441. Pipe S, Douglas K, Hwang N, Young G, Patel P, Fogarty P. PMID: 37747421.
-
Corrigendum to 'Evaluation of Venous Thromboembolism Risk Factors Reveals Subtype Heterogenicity in Children with Central Venous Catheters: A Multi-Center Study from the CHAT Consortium' [Journal of Thrombosis and Haemostasis 21/9 (2023) 2441 - 2450]. J Thromb Haemost. 2023 Dec; 21(12):3658. Jaffray J, Mosha M, Branchford B, Goldenberg NA, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Amankwah EK. PMID: 37741798; PMCID: PMC11707825.
-
Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature. Res Pract Thromb Haemost. 2023 Aug; 7(6):102194. Kizilocak H, Guerrera MF, Young G. PMID: 37732158; PMCID: PMC10507376.
-
Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults. Res Pract Thromb Haemost. 2023 Aug; 7(6):102180. Konkle BA, Oldenburg J, Pasi J, Kulkarni R, Nolan B, Mahlangu J, Young G, Brown SA, Pabinger I, Shapiro A, Négrier C, Blanchette V, Ragni MV, Dumont J, Lethagen S. PMID: 37753224; PMCID: PMC10518483.
-
Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol. 2023 Jul-Dec; 16(10):715-729. Pipe SW, Dunn AL, Young G. PMID: 37602448.
-
The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results. J Thromb Haemost. 2023 11; 21(11):3109-3116. Kenet G, Young G, Chuansumrit A, Matsushita T, Yadav V, Zak M, Male C. PMID: 37597724.
-
Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A. Haemophilia. 2023 Sep; 29(5):1234-1242. Young G, Callaghan MU, Balasa V, Soni A, Ahuja S, Roberts JC, Simpson ML, Kizilocak H, Frick A, Mokdad AG, Xing S, Caicedo J. PMID: 37553998.
-
Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort. Am J Hematol. 2023 10; 98(10):E285-E287. Batsuli G, Wheeler AP, Weyand AC, Sidonio RF, Young G. PMID: 37471655.
-
Time to revisit the classification of hemophilia: if it ain't broke, don't fix it! J Thromb Haemost. 2023 07; 21(7):1755-1756. Young G, Makris M. PMID: 37330266.
-
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors. Int J Lab Hematol. 2023 Aug; 45(4):413-424. Meijer P, Peyvandi F, Young G, Pruthi R, de Lima Montalvão S, Kitchen S. PMID: 37287431.
-
Nonfactor Therapies for Hemophilia. Hemasphere. 2023 Jun; 7(6):e911. Young G. PMID: 37292115; PMCID: PMC10247213.
-
Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023 May; 7(4):100179. Young G, Lenting PJ, Croteau SE, Nolan B, Srivastava A. PMID: 37358958; PMCID: PMC10285540.
-
Evaluation of venous thromboembolism risk factors reveals subtype heterogenicity in children with central venous catheters: a multicenter study from the Children's Hospital Acquired Thrombosis consortium. J Thromb Haemost. 2023 09; 21(9):2441-2450. Jaffray J, Mosha M, Branchford B, Goldenberg NA, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Amankwah EK. PMID: 37100395; PMCID: PMC11706574.
-
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023 04 29; 401(10386):1427-1437. Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, Tran H, Sun J, Wu R, Poloskey S, Qiu Z, Kichou S, Andersson S, Mei B, Rangarajan S. PMID: 37003287.
-
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding. Expert Rev Hematol. 2023 03; 16(sup1):107-127. Ragni MV, Young G, Batsuli G, Bisson E, Carpenter SL, Croteau SE, Cuker A, Curtis RG, Denne M, Ewenstein B, Federizo A, Frick N, Funkhouser K, George LA, Hoots WK, Jobe SM, Krava E, Langmead CJ, Lewis RJ, López J, Malec L, Mann Z, Miles ME, Neely E, Neufeld EJ, Pierce GF, Pipe SW, Pitler LR, Raffini L, Schnur KM, Shavit JA. PMID: 36920855.
-
The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A. Blood Adv. 2023 02 28; 7(4):620-629. Male C, Königs C, Dey S, Matsushita T, Millner AH, Zak M, Young G, Kenet G. PMID: 35858373; PMCID: PMC9979760.
-
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023 02 23; 388(8):706-718. Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. PMID: 36812434.
-
The dosing conundrum of emicizumab: To waste product or not? Res Pract Thromb Haemost. 2023 Feb; 7(2):100087. Young G. PMID: 36908771; PMCID: PMC9999193.
-
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 12 27; 6(24):6140-6150. Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, Croteau SE, Lambert T, Kempton CL, Pipe SW, Ko RH, Trzaskoma B, Dhalluin C, Bienz NS, Niggli M, Lehle M, Paz-Priel I, Young G, Jiménez-Yuste V. PMID: 35939785; PMCID: PMC9768240.
-
Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Res Pract Thromb Haemost. 2022 Oct; 6(7):e12793. Abrams CM, Jaffray J, Stillings A, Branchford BR, Young G, Goldenberg NA, Abajas YL, CHAT Consortium Investigators, VTE Risk Factors and Thromboprophylaxis Working Group of the Pediatric and Neonatal Thrombosis and H, Fargo J, Crary S, Kumar R, Woods G, Narang S, Cooper J, Silvey M, Garland K, Mahajerin A, Luchtman-Jones L, Torres M, Wright J, Pahl K, Armstrong K, Braunreiter C, Bakeer N, Sochet A, Hogan M, Gupta S, Knoll C, Hege K, Schaefer B, Panigrahi A, Thornburg C, Shimano K, Ahuja S, Weyand A, Boucher A, Abajas Y, Subbaswamy A, Khan O, Druzgal C, Maida D, Wheeler A, Malec L, Branchford B, Kucine NE, Prozora S. PMID: 38024326; PMCID: PMC10656282.
-
Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab. Haemophilia. 2023 Jan; 29(1):100-105. Kizilocak H, Marquez-Casas E, Malvar J, Young G. PMID: 36287631.
-
Risk factors for hospital acquired venous thromboembolism in congenital heart disease patients: A report from the children's hospital acquired thrombosis (CHAT) consortium. Thromb Res. 2022 12; 220:116-120. Silvey M, Nguyen ATH, Amankwah EK, McElwaine E, Branchford B, Stillings A, Krava E, Young G, Goldenberg N, Jaffray J. PMID: 36334398.
-
Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital-Acquired Thrombosis consortium. Res Pract Thromb Haemost. 2022 Oct; 6(7):e12810. Stephens ET, Nguyen ATH, Jaffray J, Branchford B, Amankwah EK, Goldenberg NA, Faustino EVS, Zakai NA, Stillings A, Krava E, Young G, Fargo JH. PMID: 36254253; PMCID: PMC9561357.
-
Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life. J Adv Pract Oncol. 2022 May; 13(Suppl 3):7-20. Escobar MA, Leissinger C, Young G. PMID: 35769336; PMCID: PMC9236157.
-
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022 06 14; 6(11):3422-3432. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Šalek S, Oldenburg J, Chowdary P. PMID: 35290453; PMCID: PMC9198939.
-
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul; 28(4):548-556. Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. PMID: 35475308; PMCID: PMC9542908.
-
Direct oral anticoagulants for use in paediatrics. Lancet Child Adolesc Health. 2022 03; 6(3):207-214. Jaffray J, Young G. PMID: 35033222.
-
A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium. Pediatr Crit Care Med. 2022 01 01; 23(1):e1-e9. Jaffray J, Mahajerin A, Branchford B, Nguyen ATH, Faustino EVS, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Zakai NA, Stillings A, Krava E, Amankwah EK, Young G, Goldenberg NA. PMID: 34406168; PMCID: PMC8738123.
-
Can we do something about ICH in hemophilia? Blood. 2021 12 30; 138(26):2750-2751. Young G. PMID: 34967868.
-
Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 03; 69(3):e29522. Carmona R, Kizilocak H, Marquez-Casas E, Vasquez S, Ji L, Ko RH, Young G, Jaffray J. PMID: 34963026.
-
Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response. Thromb Haemost. 2022 Jun; 122(6):913-925. Chowdary P, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Cooper A, Scalfaro E, Tiede A. PMID: 34865209; PMCID: PMC9251711.
-
Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. J Pediatr. 2022 01; 240:14-23. Male C, Monagle P, Albisetti M, Brandão LR, Young G. PMID: 34687696.
-
Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. J Thromb Haemost. 2022 01; 20(1):133-137. Jaffray J, Baumann Kreuziger L, Branchford B, Wee CP, Faustino EVS, Zakai NA, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Goldenberg NA. PMID: 34623749.
-
Emerging drugs for hemophilia A: insights into phase II and III clinical trials. Expert Opin Emerg Drugs. 2021 12; 26(4):337-350. Kizilocak H, Young G. PMID: 34601977.
-
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931. Escobar M, Castaman G, Boix SB, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha IH, Négrier C, Quon D, Recht M, Schved JF, Shapiro AD, Sidonio R, Srivastava A, Stasyshyn O, Vilchevska KV, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Macie C, Wilkinson TA, Kessler C. PMID: 34636112; PMCID: PMC9292935.
-
Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2022 Jan; 28(1):27-35. Tiede A, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Chowdary P. PMID: 34562332.
-
Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays. Haemophilia. 2021 Sep; 27(5):730-735. Kizilocak H, Marquez-Casas E, Malvar J, Carmona R, Young G. PMID: 34115433.
-
Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making. Haemophilia. 2021 Sep; 27(5):724-729. Mason JA, Young G. PMID: 34085367.
-
Management of children with hemophilia A: How emicizumab has changed the landscape. J Thromb Haemost. 2021 07; 19(7):1629-1637. Young G. PMID: 33872458.
-
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. PMID: 33512413; PMCID: PMC8065240.
-
Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opin Drug Saf. 2021 Apr; 20(4):387-396. Wang CP, Young G, Thornburg CD. PMID: 33612049.
-
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021 02 11; 137(6):763-774. Konkle BA, Walsh CE, Escobar MA, Josephson NC, Young G, von Drygalski A, McPhee SWJ, Samulski RJ, Bilic I, de la Rosa M, Reipert BM, Rottensteiner H, Scheiflinger F, Chapin JC, Ewenstein B, Monahan PE. PMID: 33067633; PMCID: PMC7885820.
-
Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27(2):211-220. Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. PMID: 33550614.
-
Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021 02; 14(2):143-148. Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. PMID: 33499681.
-
Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. Haemophilia. 2021 Jan; 27(1):164-172. Kizilocak H, Marquez-Casas E, Phei Wee C, Malvar J, Carmona R, Young G. PMID: 33245833.
-
Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child. Pediatrics. 2020 11; 146(5). Chehade H, Cachat F, Beck-Popovic M, Rotman S, Diezi L, Albisetti M, Alberio L, Young G, Rizzi M. PMID: 33122347.
-
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018. Mancuso ME, Mahlangu J, Sidonio R, Trask P, Uguen M, Chang T, Shima M, Young G, Oldenburg J, von Mackensen S. PMID: 33084175; PMCID: PMC7821108.
-
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thromb Haemost. 2021 Mar; 121(3):351-360. Schmitt C, Adamkewicz JI, Xu J, Petry C, Catalani O, Young G, Negrier C, Callaghan MU, Levy GG. PMID: 33086400; PMCID: PMC7895541.
-
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv. 2020 10 13; 4(19):4632-4639. Thom K, Lensing AWA, Nurmeev I, Bajolle F, Bonnet D, Kenet G, Massicotte MP, Karakas Z, Palumbo JS, Saracco P, Amedro P, Chain J, Chan AK, Ikeyama T, Lam JCM, Gauger C, Pap ÁF, Majumder M, Kubitza D, Smith WT, Berkowitz SD, Prins MH, Monagle P, Young G, Male C. PMID: 33002131; PMCID: PMC7556137.
-
Implications of the first FDA-approved anticoagulant in pediatrics: One ship has sailed but the next ones are at the dock. Pediatr Blood Cancer. 2020 12; 67(12):e28731. Young G. PMID: 32969168.
-
Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. J Pediatr. 2021 01; 228:252-259.e1. Jaffray J, Branchford B, Goldenberg N, Malvar J, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Sposto R, Ji L, Zakai NA, Faustino EVS, Stillings A, Krava E, Young G, Mahajerin A. PMID: 32920105; PMCID: PMC7752847.
-
Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost. 2020 Oct; 4(7):1101-1113. Chan AK, Alamelu J, Barnes C, Chuansumrit A, Garly ML, Meldgaard RM, Young G. PMID: 33134776; PMCID: PMC7590314.
-
Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation. J Thromb Haemost. 2020 09; 18(9):2205-2208. Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. PMID: 32544268.
-
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020 07; 18(7):1672-1685. Young G, Lensing AWA, Monagle P, Male C, Thelen K, Willmann S, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bajolle F, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Beyer-Westendorf J, Martinelli I, Massicotte MP, Smith WT, Berkowitz SD, Schmidt S, Price V, Prins MH, Kubitza D, EINSTEIN-Jr. Phase 3 Investigators. PMID: 32246743.
-
The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. Res Pract Thromb Haemost. 2020 Jul; 4(5):886-892. van Ommen CH, Albisetti M, Chan AK, Estepp J, Jaffray J, Kenet G, Young G, Dave J, Grosso MA, Duggal A. PMID: 32685899; PMCID: PMC7354398.
-
FondaKIDS III: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children. Pediatr Blood Cancer. 2020 08; 67(8):e28295. Shen X, Wile R, Young G. PMID: 32307822.
-
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502. Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Nogami K, Santagostino E, Pasi KJ, Khoo L, Winding B, Yuan H, Fruebis J, Rudin D, Oldenburg J. PMID: 32227570; PMCID: PMC7384031.
-
Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020 04; 13(4):313-321. Lillicrap D, Fijnvandraat K, Young G, Mancuso ME. PMID: 32186928.
-
Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children. Blood. 2020 01 16; 135(3):220-226. Jaffray J, Witmer C, O'Brien SH, Diaz R, Ji L, Krava E, Young G. PMID: 31909784.
-
Comparative validation study of risk assessment models for pediatric hospital-acquired venous thromboembolism. J Thromb Haemost. 2020 03; 18(3):633-641. Mahajerin A, Jaffray J, Branchford B, Stillings A, Krava E, Young G, Goldenberg NA, Faustino EVS. PMID: 31808292.
-
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138. Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. PMID: 31697801; PMCID: PMC6908828.
-
Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 11 28; 134(22):1973-1982. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J. PMID: 31444162; PMCID: PMC6895373.
-
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27. Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P, EINSTEIN-Jr Phase 3 Investigators. PMID: 31699660.
-
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019 Oct; 6(10):e500-e509. Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D, EINSTEIN-Jr Phase 2 Investigators. PMID: 31420317.
-
Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data. J Blood Med. 2019; 10:243-250. Escobar MA, Walsh CE, Cooper DL, Young G. PMID: 31413650; PMCID: PMC6662862.
-
Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019; 10:2040620719860025. Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G. PMID: 31275538; PMCID: PMC6598318.
-
Diagnosis and treatment of hemophilia. Clin Adv Hematol Oncol. 2019 Jun; 17(6):344-351. Kizilocak H, Young G. PMID: 31437138.
-
How I treat children with haemophilia and inhibitors. Br J Haematol. 2019 08; 186(3):400-408. Young G. PMID: 31069799.
-
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019 Jul; 25(4):676-684. Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G, Future of Immunotolerance Treatment Group. PMID: 31033112; PMCID: PMC6850066.
-
Why plasma-derived factor VIII? Haemophilia. 2019 May; 25(3):e183-e185. Aledort L, Carpenter SL, Cuker A, Kulkarni R, Recht M, Young G, Leissinger C. PMID: 30866124.
-
Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice. J Thromb Haemost. 2019 Apr; 17(4):567-573. Young GA, Perry DJ, International Prophylaxis Study Group (IPSG). PMID: 30667575.
-
Inhibitors: A Need for Eradication? Acta Haematol. 2019; 141(3):151-155. Santagostino E, Young G, Escuriola Ettingshausen C, Jimenez-Yuste V, Carcao M. PMID: 30783066.
-
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thromb J. 2018; 16:34. Lensing AWA, Male C, Young G, Kubitza D, Kenet G, Patricia Massicotte M, Chan A, Molinari AC, Nowak-Goettl U, Pap ÁF, Adalbo I, Smith WT, Mason A, Thelen K, Berkowitz SD, Crowther M, Schmidt S, Price V, Prins MH, Monagle P. PMID: 30598642; PMCID: PMC6302520.
-
Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia. Am J Hematol. 2019 02; 94(2):249-256. Ramiz S, Hartmann J, Young G, Escobar MA, Chitlur M. PMID: 30328141.
-
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J. 2018; 16:31. Kubitza D, Willmann S, Becka M, Thelen K, Young G, Brandão LR, Monagle P, Male C, Chan A, Kennet G, Martinelli I, Saracco P, Lensing AWA. PMID: 30534007; PMCID: PMC6278122.
-
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44. Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. PMID: 30427582.
-
Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2018 10 23; 2(20):2780-2782. Young G. PMID: 30352951; PMCID: PMC6199657.
-
Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 11; 11(11):835-846. Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. PMID: 30278802.
-
The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Rev Hematol. 2018 11; 11(11):857-862. Oldenburg J, Young G, Santagostino E, Escuriola Ettingshausen C. PMID: 30286680.
-
Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia. 2018 Nov; 24(6):911-920. Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G. PMID: 30248217.
-
Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res. 2018 05; 165:44-50. Prasca S, Carmona R, Ji L, Ko RH, Bhojwani D, Rawlins YA, Mittelman SD, Young G, Orgel E. PMID: 29567586; PMCID: PMC7522001.
-
A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Rev Hematol. 2018 02; 11(2):87-97. Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S. PMID: 29258406.
-
Novel therapies and current clinical progress in hemophilia A. Ther Adv Hematol. 2018 Feb; 9(2):49-61. Balkaransingh P, Young G. PMID: 29387330; PMCID: PMC5768270.
-
A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project. Thromb Res. 2018 01; 161:67-72. Jaffray J, Mahajerin A, Young G, Goldenberg N, Ji L, Sposto R, Stillings A, Krava E, Branchford B. PMID: 29207321.
-
Deep vein thrombosis in pediatric patients. Pediatr Blood Cancer. 2018 03; 65(3). Jaffray J, Young G. PMID: 29115714.
-
Anticoagulation Therapies in Children. Pediatr Clin North Am. 2017 12; 64(6):1257-1269. Young G. PMID: 29173784.
-
How I treat pediatric venous thromboembolism. Blood. 2017 09 21; 130(12):1402-1408. Young G. PMID: 28774877; PMCID: PMC5813720.
-
Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. Am J Hematol. 2017 Sep; 92(9):940-945. Young G, Escobar MA, Pipe SW, Cooper DL. PMID: 28589615.
-
Pediatric Anticoagulation: Time for a New Paradigm? J Pediatr. 2017 10; 189:21-23. Takahashi M, Young G. PMID: 28705651.
-
Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. PMID: 28691557.
-
Anticoagulation in children: Making the most of little patients and little evidence. Blood Cells Mol Dis. 2017 09; 67:48-53. Young G, Male C, van Ommen CH. PMID: 28552476.
-
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017 06 02; 117(6):1023-1030. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M, Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). PMID: 28357444.
-
Treatment of Venous Thromboembolism in Pediatric Patients. Front Pediatr. 2017; 5:26. Malec L, Young G. PMID: 28293549; PMCID: PMC5328974.
-
The perils of rivaroxaban in younger patients. Thromb Res. 2016 12; 148:154-155. Young G. PMID: 28340957.
-
Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease. Thromb Res. 2017 Mar; 151:44-50. Gupta S, Carmona R, Malvar J, Young G. PMID: 28110132.
-
Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study. Br J Haematol. 2016 Oct; 175(1):133-40. Limperger V, Kenet G, Goldenberg NA, Heller C, Holzhauer S, Junker R, Klostermeier UC, Knoefler R, Kurnik K, Krümpel A, Mesters R, Stach M, Young G, Nowak-Göttl U. PMID: 27329967.
-
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR. PMID: 27223147.
-
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8. Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, Nogami K, Young G, Cristiano LM, Dong Y, Allen G, Pierce GF, Robinson B. PMID: 26962852.
-
Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76. Young G, Collins PW, Colberg T, Chuansumrit A, Hanabusa H, Lentz SR, Mahlangu J, Mauser-Bunschoten EP, Négrier C, Oldenburg J, Patiroglu T, Santagostino E, Tehranchi R, Zak M, Karim FA. PMID: 26970716.
-
The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016 Jul 09; 388(10040):187-97. Peyvandi F, Garagiola I, Young G. PMID: 26897598.
-
The bleeding newborn: A review of presentation, diagnosis, and management. Semin Fetal Neonatal Med. 2016 Feb; 21(1):44-9. Jaffray J, Young G, Ko RH. PMID: 26778526.
-
Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence. 2015; 9:1623-30. Chaugule SS, Hay JW, Young G. PMID: 26635471; PMCID: PMC4646600.
-
Global assays in hemophilia. Semin Hematol. 2016 Jan; 53(1):40-5. Chitlur M, Young G. PMID: 26805906.
-
Anticoagulants in children and adolescents. Hematology Am Soc Hematol Educ Program. 2015; 2015:111-6. Young G. PMID: 26637709.
-
Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors. Clin Appl Thromb Hemost. 2015 Jan; 21(1):10-8. Young G, Teitel J, d'Oiron R, Leissinger C, Berntorp E. PMID: 25343956.
-
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6. Collins PW, Young G, Knobe K, Karim FA, Angchaisuksiri P, Banner C, Gürsel T, Mahlangu J, Matsushita T, Mauser-Bunschoten EP, Oldenburg J, Walsh CE, Negrier C, paradigm 2 Investigators. PMID: 25261199; PMCID: PMC4271178.
-
FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res. 2014 Sep; 134(3):643-7. Ko RH, Michieli C, Lira JL, Young G. PMID: 25087891.
-
Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013 Nov; 52(11):967-80. Yee DL, O'Brien SH, Young G. PMID: 23797535.
-
Developmental hemostasis: clinical implications from the fetus to the adolescent. Pediatr Clin North Am. 2013 Dec; 60(6):1407-17. Jaffray J, Young G. PMID: 24237979.
-
Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation. J Pediatr Surg. 2013 Sep; 48(9):1837-42. Perry R, Stein J, Young G, Ramanathan R, Seri I, Klee L, Friedlich P. PMID: 24074654.
-
Incidence of thrombosis in children with tunneled central venous access devices versus peripherally inserted central catheters (PICCs). Thromb Res. 2013 Nov; 132(5):527-30. Kanin M, Young G. PMID: 24055175.
-
A novel approach for detecting hypercoagulability utilizing thromboelastography. Thromb Res. 2013 Apr; 131(4):352-6. Ko RH, Ji L, Young G. PMID: 23419411.
-
Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013 Feb; 4(1):59-72. Witmer C, Young G. PMID: 23610614; PMCID: PMC3629762.
-
Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013 Mar 14; 121(11):1944-50. Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. PMID: 23319573; PMCID: PMC3645054.
-
Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). J Blood Med. 2012; 3:131-8. Young G, Solem CT, Hoffman K, Kabawat J, Pickard AS, Gut RZ, Cooper DL. PMID: 23152717; PMCID: PMC3496408.
-
PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res. 2012 Dec; 130(6):864-70. Young G, Auerswald G, Jimenez-Yuste V, Lambert T, Morfini M, Santagostino E, Blanchette V. PMID: 22964026.
-
Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children. Expert Rev Clin Pharmacol. 2012 Jul; 5(4):389-96. Ko RH, Young G. PMID: 22943118.
-
From boy to man: recommendations for the transition process in haemophilia. Haemophilia. 2012 Jul; 18 Suppl 5:27-32. Young G. PMID: 22757681.
-
Difficult clinical challenges in haemophilia: international experiential perspectives. Haemophilia. 2012 Jul; 18 Suppl 5:39-45. Forsyth AL, Giangrande P, Hay CR, Kenet G, Kessler CM, Knöbl PN, Llinás A, Santagostino E, Young G. PMID: 22757683.
-
Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep; 87(9):933-6. Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. PMID: 22733686; PMCID: PMC3645919.
-
Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008). Haemophilia. 2012 Nov; 18(6):990-6. Young G, Cooper DL, Gut RZ, HTRS Investigators. PMID: 22631073.
-
New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program. 2012; 2012:362-8. Young G. PMID: 23233605.
-
Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost. 2011 Oct; 37(7):802-9. Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. PMID: 22187403.
-
Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2012 May; 18(3):392-9. Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. PMID: 22171621.
-
Old and new antithrombotic drugs in neonates and infants. Semin Fetal Neonatal Med. 2011 Dec; 16(6):349-54. Young G. PMID: 21816695.
-
Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors. Am Health Drug Benefits. 2011 Jul; 4(4):219-31. Bonnet P, Gringeri A, Gomperts E, Leissinger CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E. PMID: 25126352; PMCID: PMC4125756.
-
When should prophylaxis therapy in inhibitor patients be considered? Haemophilia. 2011 Sep; 17(5):e849-57. Young G, Auerswald G, Jimenez-Yuste V, Konkle BA, Lambert T, Morfini M, Santagostino E, Blanchette V. PMID: 21418444.
-
FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011 Dec 01; 57(6):1049-54. Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. PMID: 21319285.
-
Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv. 2011 Apr 01; 77(5):671-9. Forbes TJ, Hijazi ZM, Young G, Ringewald JM, Aquino PM, Vincent RN, Qureshi AM, Rome JJ, Rhodes JF, Jones TK, Moskowitz WB, Holzer RJ, Zamora R. PMID: 21433272.
-
New anticoagulants in children: a review of recent studies and a look to the future. Thromb Res. 2011 Feb; 127(2):70-4. Young G. PMID: 21129768.
-
Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1103-9. Young G, Boshkov LK, Sullivan JE, Raffini LJ, Cox DS, Boyle DA, Kallender H, Tarka EA, Soffer J, Hursting MJ. PMID: 21488155.
-
Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population. Blood Coagul Fibrinolysis. 2010 Sep; 21 Suppl 1:S7-10. Young G. PMID: 20855989.
-
Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol. 2011 Jan; 51(1):19-28. Madabushi R, Cox DS, Hossain M, Boyle DA, Patel BR, Young G, Choi YM, Gobburu JV. PMID: 20421511.
-
Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010 Apr 27; 121(16):1838-47. Kenet G, Lütkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, Günther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rostásy K, Simioni P, Sträter RD, Young G, Nowak-Göttl U. PMID: 20385928.
-
Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia. 2010 May; 16(3):518-24. Young G, Zhang R, Miller R, Yassin D, Nugent DJ. PMID: 20028419.
-
Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children. Pediatr Blood Cancer. 2009 Aug; 53(2):179-83. Young G, Wicklund B, Neff P, Johnson C, Nugent DJ. PMID: 19415741.
-
Bivalirudin for anticoagulation in children. Pediatr Blood Cancer. 2008 Dec; 51(6):798-801. Rayapudi S, Torres A, Deshpande GG, Ross MP, Wohrley JD, Young G, Tarantino MD. PMID: 18819124.
-
Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation. 2008 Sep 23; 118(13):1373-82. Young G, Albisetti M, Bonduel M, Brandao L, Chan A, Friedrichs F, Goldenberg NA, Grabowski E, Heller C, Journeycake J, Kenet G, Krümpel A, Kurnik K, Lubetsky A, Male C, Manco-Johnson M, Mathew P, Monagle P, van Ommen H, Simioni P, Svirin P, Tormene D, Nowak-Göttl U. PMID: 18779442.
-
Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008 Jun; 19(4):276-82. Young G, Ebbesen LS, Viuff D, Di Paola J, Konkle BA, Negrier C, Pasi J, Ingerslev J. PMID: 18469548.
-
New anticoagulants in children. Hematology Am Soc Hematol Educ Program. 2008; 245-50. Young G. PMID: 19074090.
-
Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008 Mar; 14(2):287-94. Young G, Shafer FE, Rojas P, Seremetis S. PMID: 18081834.
-
Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis. 2007 Sep; 18(6):547-53. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. PMID: 17762530.
-
Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost. 2007 Aug; 5(8):1654-9. Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. PMID: 17663736.
-
Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. Blood Coagul Fibrinolysis. 2007 Mar; 18(2):97-103. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. PMID: 17287624.
-
Heparin use in children. Pediatr Res. 2007 Feb; 61(2):139-40. Young G. PMID: 17237710.
-
Diagnosis and treatment of thrombosis in children: general principles. Pediatr Blood Cancer. 2006 May 01; 46(5):540-6. Young G. PMID: 16206194.
-
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006 Apr; 148(4):489-94. Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, Weber LC, Davis ML, Lynn H, Nugent DJ, Acute ITP Study Group. PMID: 16647411.
-
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006 Jul 01; 108(1):57-62. Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, Pederson SM, Ishak LM, Nugent DJ. PMID: 16556896.
-
New approaches in the management of inhibitor patients. Acta Haematol. 2006; 115(3-4):172-9. Young G. PMID: 16549892.
-
Multifocal Castleman disease in pediatrics: case report. J Pediatr Hematol Oncol. 2005 Dec; 27(12):666-9. Baserga M, Rosin M, Schoen M, Young G. PMID: 16344673.
-
Pediatric stroke and methylenetetrahydrofolate reductase polymorphisms: an examination of C677T and A1298C mutations. J Pediatr Hematol Oncol. 2005 Nov; 27(11):590-3. Rook JL, Nugent DJ, Young G. PMID: 16282888.
-
Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005 Feb; 7(2):143-6. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C. PMID: 15714083.
-
Therapy for haemophilia: recent advances and goals for the future. Expert Opin Emerg Drugs. 2005 Feb; 10(1):173-84. Young G, Aledort L. PMID: 15757411.
-
Can we rise to yet another challenge? Prof Nurse. 2004 Sep; 20(1):6-7. Young G. PMID: 15468769.
-
Current and future antithrombotic agents in children. Expert Rev Cardiovasc Ther. 2004 Jul; 2(4):523-34. Young G. PMID: 15225112.
-
Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion. 2004; 19(5):283-8. Young G, Yonekawa KE, Nakagawa P, Nugent DJ. PMID: 15506032.
US